BioSpace News Archive

Quest International, Inc., a global IT managed services provider specializing in the healthcare industry, announced today its initiative to prevent and increase awareness of many forms of cyberattacks such as denial of service (DoS) attacks, phishing attacks, man-in-the-middle (MitM) attack and others that can cripple healthcare businesses.

Aries Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved AEMCOLO™ (rifamycin) 194mg delayed-release tablets, a new minimally absorbed antibiotic that is delivered to the colon, for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli (E. coli).

Company to highlight progress of Phase 3 trial of lead drug, CPP-1X/sul, for Familial Adenomatous Polyposis

PERSERIS delivers risperidone in a new once-monthly extended-release delivery system. Neither a loading dose nor any supplemental oral risperidone is recommended.

Bausch Health Companies Inc. today announced that the company will participate in three upcoming investor conferences.

Theravance Biopharma, Inc. announced today that members of management will participate in fireside chats at two upcoming investor conferences

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation

Americans are cutting back on sugars: nearly half of consumers (47 percent) reported planning to eat less sugar or buy more ‘no sugar added’ products this year. Yet, a trip around the Thanksgiving table shows that hidden sugars are piling up, long before the pumpkin pie.

ORIC Pharmaceuticals announced today that it will present at two upcoming investor conferences.

Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML